BioCryst Pharmaceuticals (NASDAQ:BCRX) to Release Q3 2008 Earnings October 31

BioCryst Pharmaceuticals (NASDAQ:BCRX) will release the third quarter earnings for 2008 on Friday, October 31.  A conference call will be held that morning at 8:30 am to discuss the financial results.  Speakers at the conference call include BioCryst President and Chief Executive Officer Jon P. Stonehouse, Chief Financial Officer Stuart Grant and Chief Medical Officer Dr. William P. Sheridan.

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. It integrates the necessary disciplines of biology, crystallography, medicinal chemistry and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals.

The Company’s product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). An oral formulation of the compound is in a Phase IIb trial. Biocryst’s second drug candidate is peramivir, an inhibitor of influenza neuraminidase. Peramivir is in development for the treatment of influenza with two parenteral formulations, intramuscular (i.m.) and intravenous (i.v.). The Company’s other drug candidate in clinical trials is the second generation PNP inhibitor, BCX-4208.